ICER’s Positive Cost-Effectiveness Assessment Lends Support For New Sickle Cell Disease Gene Therapies The important takeaway is that these gene therapies can be cost-effective and don’t necessarily break the bank. Too often the conversation around a therapy's price is fixated on eye-popping numbers and not value. It's laudable that ICER has redirected us to a discussion of value.